Osteoporosis is a Predictive Factor for Nephrolithiasis in an Adult Free-Living Caucasian Population From Southern Italy: A Longitudinal Retrospective Study Based on a General Practice Database

Domenico Rendina1 · Lanfranco D’Elia1 · Marco Evangelista1 · Gianpaolo De Filippo2 · Alfonso Giaquinto1 · Biagio Barone3 · Gaetano Piccinocchi4 · Domenico Prezioso3 · Pasquale Strazzullo1

Received: 5 April 2020 / Accepted: 23 July 2020 / Published online: 1 August 2020 © The Author(s) 2020

Abstract
Osteoporosis and nephrolithiasis are common multifactorial disorders with high incidence and prevalence in the adult population worldwide. Both are associated with high morbidity and mortality if not correctly diagnosed and accurately treated. Nephrolithiasis is considered a risk factor for reduced bone mineral density. Aim of this retrospective longitudinal study was to evaluate if osteoporosis is a predictive factor for the nephrolithiasis occurrence. Free-living subjects referring to “COMEGEN” general practitioners cooperative operating in Naples, Southern Italy. Twelve thousand seven hundred ninety-four Caucasian subjects (12,165 female) who performed bone mineral density by dual-energy X-ray absorptiometry and have a negative personal history for nephrolithiasis. Subjects aged less than 40 years or with signs or symptoms suggestive of secondary osteoporosis were excluded from the study. In a mean lapse of time of 19.5 months, 516 subjects had an incident episode of nephrolithiasis. Subjects with osteoporosis had an increased risk of nephrolithiasis than subjects without osteoporosis (Hazard Ratio = 1.33, 95% Confidence Interval 1.01–1.74, p=0.04). Free-living adult subjects over the age of 40 with idiopathic osteoporosis have an increased risk of incident nephrolithiasis, suggesting the advisability of appropriate investigation and treatment of the metabolic alterations predisposing to nephrolithiasis in patients with osteoporosis. The study protocol was approved by the ASL Napoli 1 Ethical Committee, protocol number 0018508/2018

Keywords Osteoporosis · Nephrolithiasis · Epidemiological survey

Introduction
Osteoporosis and nephrolithiasis are two common multifactorial disorders characterized by high incidence and prevalence in the adult population worldwide [1]. Both show high morbidity and mortality if not correctly diagnosed and accurately treated [1]. Osteoporosis is defined as a decrease in bone density that results in micro-architecture deterioration, which predisposes affected patients to fractures [2].

It is recognized as the most common form of metabolic bone disease, with an estimated 200 million people affected worldwide [3]. Approximately 30% of all postmenopausal women have osteoporosis in the USA and in Europe. At least 40% of these women and 15–30% of men will sustain one or more fragility fractures in their remaining lifetime [2]. Ageing of populations worldwide will be responsible for a major increase in the incidence of osteoporosis, particularly amongst postmenopausal women. The Italian National Health Institute (Istituto Superiore di Sanità, ISS) estimates that the prevalence of osteoporosis and osteopenia in the Italian population older than 40 years is 14.5% and 34.5% in males and 22.8% and 42.3% in females, respectively [4]. Symptomatic fractures occur in 21/1000 osteoporotic subjects per year with an estimated cost of 3 billion euro per year. Less than 20% of patients with symptomatic fractures reach a complete restitutio ad integrum [2]. Nephrolithiasis refers to the presence of crystalline stones (calculi) within the urinary system (kidneys and ureters) [5]. It affects nearly
1 in 11 individuals in the USA at some point in their lives, and there is evidence that the number of those who have had a stone is rising [5]. It has been estimated that more than 5% of Italian population over 35 years have already had an episode of kidney stones, and that kidney stones required more than 100,000 hospitalizations per year, with a cost that exceeds 200,000 Euro millions per year [6]. Similar epidemiological data are available in almost all industrialised countries [7]. Other than epidemiological data, both osteoporosis and nephrolithiasis share common pathogenic factors, such as unhealthy eating habits involving high salt, high sugar and inadequate calcium intakes as well as low physical activity and disorders of calcium–phosphate and vitamin D homeostasis [8–12]. Nephrolithiasis is considered a risk factor for reduced bone mineral density and osteoporosis [13], but data evaluating if osteoporosis predisposes to the occurrence of nephrolithiasis are lacking. Aim of this study was to assess if osteoporosis is a predictive factor for the occurrence of nephrolithiasis via a retrospective longitudinal study. The study was performed in free-living Caucasian adult subjects afferent to the Local Health Unit (Azienda Sanitaria Locale, ASL) Naples 1, Campania, Southern Italy.

Methods

The study was based on the clinical records of 180,724 patients followed by the general practitioners (GPs) afferent to the “COMEGEN” (COoperativa di MEdicinaGENerale) Medical Cooperative operating within the ASL Naples 1. As of June 1st 2018, the participating GPs selected amongst their patients those who performed an evaluation of bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA, ICD9 code 8898) within December 1st 2017, according to Italian Ministerial Decree regulating Essential Assistance Levels (EAL) in osteoporosis management [14]. From the patients’ medical records, we collected data regarding weight, height, body mass index (BMI), age, sex (M = male, F = female), smoking habits (current, previous or never smoker [15], date of DXA, occurrence of nephrolithiasis (ICD9 codes 5920 to 5929) and relative date, and any pharmacological treatment for osteoporosis (i.e. single or combined use of calcium salts, vitamin D and analogues, selective estrogen receptor modulators, bisphosphonates, teriparatide, strontium ranelate and/or denosumab) via a predefined data collection form. The selected patients were univocally identified with a sequential alphanumeric code, and their data were collected in an electronic file, elaborated by D.R., G.D.F. and M.E. Informed consent was obtained from all individual participants included in the study. The study protocol was approved by the Ethical Committee of ASL Napoli 1, protocol number 0018508/2018.

Diagnostic Criteria

The diagnosis of osteoporosis was based on a T-score value measured by DXA ≤ − 2.5 in the lumbar spine, total hip or femoral neck, according to the World Health Organization (WHO) diagnostic criteria [16]. Subjects with a lumbar or femoral T-score > − 2.5 and a personal history negative for assumption of antiresorptive drugs were used as controls. The diagnosis of nephrolithiasis was based on the instrumental evidence of kidney stones and/or personal history of kidney stone ejection.

Exclusion Criteria

A patient was excluded if the diagnosis of nephrolithiasis was antecedent the DXA date. Other exclusion criteria were: age lower than 40 years, malabsorption syndromes (ICD9 codes 5793 to 5799), rheumatoid arthritis (ICD9 code 7140), long-term immobilization, moderate to severe chronic kidney disease (estimated glomerular filtration rate < 60 ml/min; ICD9 codes 5853 to 5859, 586 and 6393), hyperthyroidism (ICD9 codes 24200 to 24291), primary hyperparathyroidism (ICD9 codes 25200 to 25208), hypoparathyroidism (ICD9 code 2521), Cushing’s syndrome (ICD9 code 2550), chronic liver disease (ICD9 codes 5710 to 5719), prostate cancer (ICD9 codes 185, 2334, 2365), pituitary tumours (ICD9 codes 1943, 2273, 2370), surgical history of terminal ileal resection (ICD9 code 4562), gastrectomy or small bowel bypass (ICD9 codes 430 to 4499), orchiectomy (ICD9 codes 622 to 6242), eating disorders (ICD9 codes 3071 and 30750 to 30759), alcoholism (ICD9 codes 30390 to 30393), regular use of gonadotropin-releasing hormone agonist, glucocorticoids, anticonvulsants, heparin, vitamin A, cytotoxic agents and antiandrogens, incomplete data collection, and osteoporosis therapy not compliant to Italian Medicine Agency (Agenzia Italiana del Farmaco, AIFA) prescriptive criteria [17]. In this document, the AIFA prescribes “to guarantee before and during anti-osteoporotic treatment an adequate intake of calcium and vitamin D, resorting, if diet and sun exposure are inadequate, to supplements with calcium salts and vitamin D3 (not to its hydroxylated metabolites)” [17].

Statistical Analysis

All statistical analyses were performed using the IBM SPSS Statistics software, version 23 (International Business Machines Corporation (IBM), Armonk, New York) by L.D.E, who did not participate to the data extraction from “COMEGEN” Medical Cooperative database. Analysis of variance (ANOVA) or Chi-squared test were used to assess differences in baseline main characteristics. Cox
proportional hazard models were used to estimate hazard ratios (HRs)—with 95% confidence intervals (CIs)—for the risk of nephrolithiasis incidence in subjects with osteoporosis. The multivariate model was adjusted for age, sex, BMI, smoking habits, and treatment for osteoporosis. Subjects who did not develop nephrolithiasis were censored at data extraction. All reported \( p \) values are two-sided, and the significant level was set at \( p < 0.05 \).

## Results

According to the inclusion and exclusion criteria (Fig. 1), we selected the medical records of 12,794 patients (12,165 F: 629 M; mean age 69.3 ± 10.0 years; BMI 26.8 ± 4.8 kg/m\(^2\)): 10,157 subjects (9758 F: 399 M; 70.0 ± 9.7 years; BMI 26.7 ± 4.7 kg/m\(^2\)) have clinical diagnosis of osteoporosis whereas the remaining 2637 subjects (2407 F: 230 M; mean age 66.6 ± 10.7 years; BMI 27.2 ± 5.0 kg/m\(^2\)), which have a BMD > −2.5 T-score, were considered as controls. All of them have a personal history negative for nephrolithiasis at the time of DXA execution.

In a mean lapse of time of 19.5 ± 14.4 months (minimum: 1.5 months; maximum: 113.7 months, median: 15.9 months; person-months: 249,554, rate: 2.1 cases/1000 person-months), 516 subjects had clinical diagnosis of nephrolithiasis occurred after the execution of the DXA (4%; 494 F: 22 M; mean age 70.8 ± 8.8 years; BMI 26.6 ± 4.8 kg/m\(^2\)); 447 with osteoporosis; average nephrolithiasis onset: 15.4 ± 11.2 months). The percentage incidence of nephrolithiasis in subjects divided according to age range was 2.1%, 2.2%, 4.3%, 5.0% and 4.0% in subjects aged between 40 and 50 years (n = 329), between 51 and 60 years (n = 2385), between 61 and 70 years (n = 4169), between 71 and 80 years (n = 1752) and > 81 years (n = 1752), respectively (\( p = 0.001 \)). The percentage number of subject developing nephrolithiasis was higher amongst subjects with osteoporosis compared with patients without osteoporosis (4.4% vs 2.6%, for subjects with and without osteoporosis respectively; \( p < 0.001 \)). At the univariate Cox model, osteoporosis diagnosis at baseline was associated with an increased risk of nephrolithiasis (HR = 1.33, 95% CI 1.03–1.71, \( p = 0.03 \)). This association remained significant in a model adjusted for age, sex, BMI, treatment for osteoporosis and smoking habits (HR = 1.33, 95% CI 1.01–1.74, 1.27–1.74).

---

**Fig. 1** Study flow chart. ASL Na 1: Local Health Unit (in Italian: Azienda Sanitaria Locale) Naples 1. BMD: Bone mineral density. DXA: Dual-Energy X-ray absorptiometry. EAL: Essential Assistance Levels in osteoporosis management [14]. AIFA: Italian Medicine Agency (in Italian: Agenzia Italiana del FArmaco) [17].§: Subject with malabsorption syndromes (ICD9 codes 5793 to 5799), rheumatoid arthritis (ICD9 code 7140), long-term immobilization, moderate to severe chronic kidney disease (ICD9 codes 5853 to 5859, 586 and 6393), hyperthyroidism (ICD9 codes 24200 to 24291), primary hyperparathyroidism (ICD9 codes 25200 to 25208), hypoparathyroidism (ICD9 code 2521), Cushing’s syndrome (ICD9 code 2550), chronic liver disease (ICD9 codes 5710 to 5719), prostate cancer (ICD9 codes 185, 2334, 2365), pituitary tumours (ICD9 codes 1943, 2273, 2370), surgical history of terminal ileal resection (ICD9 code 4562), gastrectomy or small bowel bypass (ICD9 codes 430 to 4499), orchietomy (ICD9 codes 622 to 6242), eating disorders (ICD9 codes 3071 and 30750 to 30759), alcoholism (ICD9 codes 30390 to 30393), regular use of gonadotropin-releasing hormone agonist, glucocorticoids, anticonvulsants, heparin, vitamin A, cytotoxic agents and antiandrogens, were excluded from the study.
Discussion

The results of our study demonstrate that in free-living adult subjects over 40 years old without personal history of nephrolithiasis, idiopathic osteoporosis is a predictive factor for the incidence of nephrolithiasis. The predictive value of osteoporosis remains after correction for sex, BMI, age, smoking habits and treatment for osteoporosis. The relevance of study results is emphasized by the high prevalence of both disorders in the general population and the high rate of nephrolithiasis incidence after the age of 40 [1]. A recent meta-analysis, including 28 case-controls studies (1595 patients with nephrolithiasis compared to 3402 healthy controls), demonstrated that nephrolithiasis is associated with lower BMD and increased risk of osteoporosis and fractures [13]. A subsequent prospective study confirmed that nephrolithiasis could be considered a risk factor for reduced BMD and occurrence of osteoporosis [18]. To our best knowledge, however, no data are available in the international literature indicating that osteoporosis is a predictive factor for the incidence of nephrolithiasis in the adult population. In accordance with our results, Prochaska et al. demonstrated in the Nurses’ Health Study II population that a reduced bone density was an independent risk factor for incident kidney stone and that the use of bisphosphonate was associated with lower risk of incident kidney stones [19]. Some data suggest a pathogenic relationship between osteoporosis and nephrolithiasis. Calcium intake is one of the many factors affecting the development of peak bone mass and preservation of bone mass in adults [20]. Epidemiological studies demonstrate a progressive reduction in dietary calcium intake of subjects with increasing age, resulting in a negative calcium balance [21, 22]. This mechanism, in turn, significantly increases the risk of osteoporosis and calcium nephrolithiasis over time. Calcium dietary intake is a key factor for oxalate absorption and excretion, which is one of the most potent promoters of calcium nephrolithiasis [23]. The reduction of calcium dietary intake decreases the calcium concentration in the intestinal lumen and prevents the formation of insoluble and non-absorbable calcium–oxalate salts. In this way, a higher quantity of soluble oxalate salts remains free in the intestinal lumen and can be easily absorbed and excreted by kidney, increasing urinary oxalate excretion, a significant metabolic risk factor for nephrolithiasis [24, 25]. In addition, considering that the follicular stimulating hormone is known to have a stimulatory effect on the osteoclast activity, its increase after menopause and andropause could also play a significant role in the pathogenesis of both nephrolithiasis and osteoporosis, increasing bone loss and urinary calcium excretion [26, 27]. Finally, experimental studies suggest a possible

Table 1 Risk factors for incidence of nephrolithiasis in free-living subjects from southern Italy over 40 years old

| Risk factor                                      | p     | HR    | 95% CI   |
|--------------------------------------------------|-------|-------|----------|
| Osteoporosis diagnosis (y/n)                      | 0.04  | 1.33  | 1.01     |
| Age (years)                                      | 0.02  | 0.99  | 0.98     |
| Sex (m/f)                                        | 0.52  | 0.87  | 0.56     |
| BMI (Kg/m²)                                      | 0.22  | 0.99  | 0.97     |
| Osteoporosis treatment (y/n)                      | 0.39  | 1.15  | 0.84     |
| Current smokers (y/n)                            | 0.18  | 1.17  | 0.93     |
| Previous smokers (y/n)                           | 0.68  | 1.08  | 0.73     |

Osteoporosis diagnosis was rendered according to the World Health Organization (WHO) diagnostic criteria: T-score value measured by Dual-Energy X-ray absorptiometry ≤ − 2.5 in the lumbar spine, total hip or femoral neck [14]. HR: hazard ratio. CI: confidence interval. BMI: body mass index. Osteoporosis treatment: current or previous single or combine use of calcium salts, vitamin D and analogues, selective estrogenic receptor modulators, bisphosphonates, teriparatide, strontium ranelate, or denosumab Y/n yes or not. M/f male or female

Fig. 2 Time-dependent likelihood of the occurrence of nephrolithiasis. Dotted line and continuous line denote patients with or without osteoporosis at baseline, respectively

\( p = 0.04 \); Table 1) as well as analysing only subject receiving the clinical diagnosis of nephrolithiasis at least 6 months after the DXA execution (\( n = 394, 3.8\% ; 375 F : 19 M ; \) mean age 71.6 ± 8.7 years; BMI 26.8 ± 4.7 kg/m²; mean follow up time: 23.3 months, HR = 1.50, 95% CI 1.08–2.09, \( p = 0.01 \)). The time-dependent likelihood of the occurrence of nephrolithiasis in patients with or without osteoporosis was reported in Fig. 2.
relationship between hypocitraturia, a recognized metabolic risk factor for calcium nephrolithiasis, and reduced BMD and osteoporosis [28, 29]. For this study we used an administrative database. According to Johnson et al., this study methodology shows advantages and limits [30]. In this regard, it should be noted that the definition of osteoporosis based upon administrative health database achieves an acceptable level of sensitivity, specificity, and accuracy, in particular when the assumption of anti-osteoporotic drugs was used as additional information in the query formulation, as in our study [31]. In addition, the use of ICD-9 coding for urinary calculi is sufficiently valid to be useful in studies using administrative data to analyze nephrolithiasis incidence [32]. Additional strengths of our study are the high sample size and the use of stringent diagnostic criteria that permitted the recruitment of subjects with or without idiopathic osteoporosis and nephrolithiasis. The most relevant and common causes of secondary osteoporosis and nephrolithiasis were excluded. Moreover, both the diagnosis of osteoporosis and that of nephrolithiasis were performed by qualified physicians not involved in the statistical analysis of collected data using strong and objective clinical criteria. Finally, the control subjects were selected based on DXA T-score $> -2.5$ and thus were not osteoporotic, according to WHO diagnostic criteria for osteoporosis. Some limits of the study are also evident. This is not a prospective study stricto sensu. We are also unable (a) to perform a “dose effect” analysis to observe if the grade of reduction of BMD, evaluated by MOC-DXA, is associated with a higher risk of nephrolithiasis; (b) to evaluate if the anatomical site of DXA exam furnishing pathological data (i.e. lumbar, femoral or ulnar site) influences the study results; (c) to assess the type of renal calculi occurring in patients with osteoporosis; (d) to evaluate the role of metabolic risk factor for both osteoporosis and nephrolithiasis, i.e. hypercalcemia, hyperuricemia, and hypocitraturia, in the pathogenesis of the observed association; and (e) to perform a multivariate analysis which take into account the dietary habits of study cohorts. It is finally possible that episodes of asymptomatic nephrolithiasis linked to stones as small as grain of sand were not reported in the database. All these limits are principally linked to kind of data used in this study which is based on administrative data [30]. We also excluded from the study subjects with a moderate to severe chronic kidney disease (CKD), considering that these patients have an increased risk of developing disorders of bone and mineral metabolism, i.e. CKD-mineral and bone disorder (CKD–MBD), requiring an integrated approach [33]. We then limited the analysis to subjects with low risk of CKD. Further studies, using different methodologies, are needed to clarify the possible influence of aforementioned factors, in particular dietary habits and values of GFR identifying subjects at low risk of CKD, in the pathogenesis of increased risk for nephrolithiasis observed in subjects with osteoporosis. In the examined cohort there was a large majority of female subjects (more than 95%); however, it should be noted that this is the first study that analysed both disorders in more than 400 male subjects over 40 years old. Based on our study results, patients with osteoporosis should be evaluated for nephrolithiasis occurrence. We suggest for patients with idiopathic osteoporosis to perform an abdomen ultrasonography and a complete evaluation of metabolic risk factors for nephrolithiasis (i.e. urinary excretion of calcium, oxalate, citrate, magnesium, phosphate and urate) within 1 year from osteoporosis diagnosis and later on at least once a year. Considering the distribution of nephrolithiasis incidence in subjects with different age ranges, this approach appears particularly indicated in subjects over the age of 61. Regarding possible medical interventions for a correct primary prevention of nephrolithiasis in patients with idiopathic osteoporosis, it should be noted that the non-pharmacologic interventions advised for the prevention and management of osteoporosis and nephrolithiasis are similar. Both include avoidance of weight gain or reduction of overweight, avoidance of smoking and alcohol abuse and regular practice of physical activity [34]. In addition, for prevention of cardiovascular disease, osteoporosis and nephrolithiasis, a normal calcium (1.2–1.5 g a day) low sodium diet (<5 g of salt a day), with large consumption of vegetable proteins and a water intake of at least 2 L per day are also recommended [10, 35–37]. According to Ferraro et al. [35], this lifestyle and nutritional approach reduces by over 60% the risk of nephrolithiasis. Regarding pharmacological treatment of osteoporosis and nephrolithiasis, considering the role of citrate in the pathogenesis of both disorders, we propose they will be carried out ad hoc clinical trials should be performed to evaluate the use of this alkalinizing agents for treatment of both these strictly related disorders [38, 39]. In conclusion, the study results demonstrate that free-living adult subjects over the age of 40 with idiopathic osteoporosis have an increased risk of incident nephrolithiasis, suggesting the advisability of appropriate investigation and treatment of the metabolic alterations predisposing to nephrolithiasis in patients with osteoporosis.

Acknowledgements Open access funding provided by Università degli Studi di Napoli Federico II within the CRUI-CARE Agreement.

Author Contributions DR, GDF, DP, GP and PS designed the study. DR, ME, AG, GP, BB and GDF assisted with data preparation and analysis. LD analyzed and interpreted the data. DR, GDF, LD, DP and PS supervised the study and provided clinical expertise. DR, GDF, LD, AG, BB, and ME drafted the manuscript. DR is the guarantor and attests that all listed authors meet authorship criteria. All authors

© Springer
revised the paper critically for intellectual content and approved the final version. All authors agree to be accountable for the work and to ensure that any questions relating to the accuracy and integrity of the paper are investigated and properly resolved.

**Funding** This was an unfunded project.

**Compliance with Ethical Standards**

**Conflict of interest** All authors namely (Domenico Rendina, Lanfranco D’Elia, Marco Evangelista, Gianpaolo De Filippo, Alfonso Giaquinto, Biagio Barone, Gaetano Piccinocchi, Domenico Prezioso, Pasquale Strazzullo) declare that there are no support from any organization for the submitted work. The authors declare that they have no conflict of interest.

**Human and Animal Rights and Informed Consent** All procedures performed in this study, which involves human participants, were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent has been obtained from each patient or subject after full explanation of the purpose and nature of all used procedures. The study protocol was approved by the ASL Napoli 1 Ethical Committee, protocol number 0018508/2018. Informed consent was obtained from all individual participants included in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW (2009) Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 94:1853–1878. https://doi.org/10.1210/jc.2008-2291
2. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, National LR, Foundation O (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381. https://doi.org/10.1007/s00198-014-2794-2
3. International Osteoporosis Foundation (2019) Facts and Statistics. Available at https://www.iofbonehealth.org/facts-statistics. Accessed 31 Mar 2020
4. Italian Major Health Institute (2019) Focus on osteoporosis. Available at https://www.epicentro.iss.it/focus/osteoporosi/osteoporosi i. Accessed 31 Mar 2020
5. Ziemia JB, Matlaga BR (2017) Epidemiology and economics of nephrolithiasis. InvestigClinUrol 58:299–306. https://doi.org/10.1111/icu.2017.58.5.299
6. Association of Italian Urologists (2019) Guideline on Urinary Stones 2019. Available at https://www.auro.it/linee-guida/09_CALCOLOSI%2520URINARIA.pdf. Accessed 31 Mar 2020
7. European Association of Urology (2019) European Association of Urology Guidelines 2018 edition 2019. Available at https://uroweb.org/wp-content/uploads/Guidelines_WebVersion_Complete-1.pdf. Accessed 31 Mar 2020
8. Fatahi S, Namazi N, Larijani B, Azadbakht L (2018) The association of dietary and urinary sodium with bone mineral density and risk of osteoporosis: a systematic review and meta-analysis. J Am Coll Nutr 37:522–532. https://doi.org/10.1080/07315724.2018.1431161
9. Ticinesi A, Nouvenne A, Maalouf NM, Borghi L, Meschi T (2016) Salt and nephrolithiasis. Nephrol Dial Transplant 31:39–45. https://doi.org/10.1093/ndt/gfu243
10. Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferrarro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella M, Milliner D, Premering GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC, Consensus Conference Group (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29:715–734. https://doi.org/10.1007/s40620-016-0329-y
11. Sakhaee K (2008) Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens 17:304–309. https://doi.org/10.1097/MNH.0b013e32828b5f4d
12. Rendina D, De Filippo G, Muscariello R, De Palma D, Fiengo A, De Pascale F, Strazzullo P (2014) Vitamin D and cardiometabolic disorders. High Blood Press Cardiovasc Prev 21:251–256. https://doi.org/10.1007/s40292-014-0060-5
13. Lucato P, Trevisan C, Stubbs B, Zanforlini BM, Solmi M, Luchini C, Girotti G, Pizzato S, Manzato E, Sereggi G, Giannini S, Fusaro M, Veronese N (2016) Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis. Osteoporos Int 27:3155–3164. https://doi.org/10.1007/s00198-016-3658-8
14. Italian Ministry of Health (2005) Osteoporosis and Bone Mineral Density. Available at https://www.salute.gov.it/imgs/C_17_pubblicazioni_1171_allegato.pdf. Accessed 30 May 2020
15. Rendina D, De Palma D, De Filippo G, De Pascale F, Muscariello R, Ippolito R, Fazio V, Fiengo A, Benvenuto D, Strazzullo P, Galletti F (2015) Prevalence of simple nodular goiter and Hashimoto’s thyroiditis in current, previous, and never smokers in a geographical area with mild iodine deficiency. Horm Metab Res 47:214–219. https://doi.org/10.1055/s-0034-1387702
16. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141. https://doi.org/10.1002/jbmr.5650090802
17. Italian Medicines Agency (AIFA) (2019) Note 79 of Italian Medicines Agency for the appropriate use of the drugs 2019. Available at https://www.agenziafarmaco.gov.it/content/nota-79. Accessed 31 Mar 2020
18. Sakhaee K, Maalouf NM, Poindexter J, Adams-Huet B, Moe OW (2017) Relationship between urinary calcium and bone mineral density in patients with calcium nephrolithiasis. J Urol 197:1472–1477. https://doi.org/10.1016/j.juro.2017.01.002
19. Prochaska M, Taylor E, Vaidya A, Curhan G (2017) Low bone density and bisphosphonate use and the risk of kidney stones. Clin J Am Soc Nephrol 12:1284–1290. https://doi.org/10.2215/CJN.01420217
20. Balk EM, Adam GP, Langberg VN, Earley A, Clark P, Ebeling PR, Mithal A, Rizzoli R, Zerbini CAF, Pierroz DD, Dawson-Hughes B, International Osteoporosis Foundation Calcium Steering Committee (2017) Global dietary calcium intake
among adults: a systematic review. Osteoporos Int 28:3315–3324. https://doi.org/10.1007/s00198-017-4230-x
21. Food and Agriculture Organization (2019). Calcium intake levels in the United States: issues and considerations 2019. Available at https://www.fao.org/3/W7336T/w7336t06.h.htm. Accessed 31 Mar 2020
22. Gaddi A, Cicero AF, Wani FO, Dormi A, Pasquarelli V, D'Addato S (2001) The realization of a project aimed at reducing the plasmatic lipid level in a large Italian population improves the mean calcium daily intake: the Brisighella Study. Eur J Clin Nutr 55:97–106. https://doi.org/10.1038/sj.ejcn.1601123
23. Marengo SR, Romani AM (2008) Oxalate in renal stone disease: the terminal metabolite that just won’t go away. Nat Clin Pract Nephrol 4:368–377. https://doi.org/10.1038/ncpne ph0845
24. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A (2002) Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346:77–84. https://doi.org/10.1056/NEJMoa010369
25. Lieske JC, Tremaine WJ, De Simone C, O’Connor HM, Li X, Bergstralh EJ, Goldfarb D (2010) Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int 78:178–185. https://doi.org/10.1038/ki.2010.310
26. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M (2006) FSH directly regulates bone mass. Cell 125:247–260. https://doi.org/10.1016/j.cell.2006.01.051
27. Rendina D, Gianfrancesco F, De Filippo G, Merlotti D, Esposito T, Mingione A, Nuti R, Strazzullo P, Mossetti G, Gennari L (2010) FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol 163:165–172. https://doi.org/10.1530/EJE-10-0043
28. Caudarella R, Vescini F, Buffa A, Stefoni S (2003) Citrate and mineral metabolism: kidney stones and bone disease. Front Biosci 8:s1084–s1106. https://doi.org/10.2741/1119
29. Vescini F, Buffa A, La Manna G, Ciavatti A, Rizzoli E, Bottura A, Stefoni S, Caudarella R (2005) Long-term potassium citrate therapy and bone mineral density in idiopathic calcium stone formers. J Endocrinol Invest 28:218–222. https://doi.org/10.1007/bf03345376
30. Johnson EK, Nelson CP (2013) Values and pitfalls of the use of administrative databases for outcomes assessment. J Urol 190:17–18. https://doi.org/10.1016/j.juro.2013.04.048
31. Leslie WD, Lix LM, Yogendran MS (2011) Validation of a case definition for osteoporosis disease surveillance. Osteoporos Int 22:37–46. https://doi.org/10.1007/s00198-010-1225-2
32. Semins MJ, Trock BJ, Matlaga BR (2010) Validity of administrative coding in identifying patients with upper urinary tract calculi. J Urol 184:190–192. https://doi.org/10.1016/j.juro.2010.03.011
33. National Kidney Foundation. (2020) Bone metabolism in CKD. Current guidelines. Available at https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf. Accessed 19 July 2020
34. Akkawi I, Zmerly H (2018) Osteoporosis: current concepts. Joints 6:122–127. https://doi.org/10.1055/s-0038-1660790
35. Ferraro PM, Taylor EN, Gambaro G, Curchan GC (2017) Dietary and lifestyle risk factors associated with incident kidney stones in men and women. J Urol 198:858–863. https://doi.org/10.1016/j.juro.2017.03.124
36. Iacoviello L, Bonaccio M, Cairella G, Catani MV, Costanzo S, D’Elia L, Giacco R, Rendina D, Sabino P, Savini I, Strazzullo P, Working Group for Nutrition, and Stroke (2018) Diet and primary prevention of stroke: systematic review and dietary recommendations by the ad hoc Working Group of the Italian Society of Human Nutrition. Nutr Metab Cardiovasc Dis 28(309):334. https://doi.org/10.1016/j.numec d.2017.12.010
37. Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, Ferraro M, Gambaro G, Geloia M, Guttilla A, Iliano E, Martino M, Meschi T, Messa P, Miano R, Napodano G, Nouvenne A, Rendina D, Rocco F, Rosa M, Sanseverino R, Salerno A, Spatafora S, Tasca A, Ticinesi A, Travaglini F, Trinchieri A, Vespasiani G, Zattoni F (2015) Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group. Arch Ital Urol Androl 87:105–120. https://doi.org/10.4081/aiua.2015.2.105
38. Granchi D, Baldini N, Ullivieri FM, Caudarella R (2019) Role of citrate in pathophysiology and medical management of bone diseases. Nutrients 11:2576. https://doi.org/10.3390/nu11112576
39. Palermo A, Naciu AM, Tabacco G, Fanfrini S, Trimboli P, Vescini F, Falchetti A (2019) Calcium citrate: from biochemistry and physiology to clinical applications. Rev Endocr Metab Disord 20:353–364. https://doi.org/10.1007/s1154-019-09520-0

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.